Family, music, rocks, fish — Doc Sinclair is a man of many passions. As he faces brain cancer, he strives to maintain an active, full life.
Decades of hiking and rock climbing taught Janice Armbrust how to handle the greatest uphill battle of her life: one day — one step — at a time.
For Joël Bernier, music has always been a source of joy and purpose. He rediscovered its power following a glioblastoma diagnosis.
Mike Hugo has packed a lot of life in his years, and he wants to teach his daughters to live with the same vigor and resolve.
Linda Long always saw the road ahead as she pursued her dream, making history in the Philadelphia Fire Department. Then she was diagnosed with glioblastoma.
A glioblastoma diagnosis led Jovan Knutson to reevaluate what is most important to her. She has found joy in the moment, and with it, a renewed sense of purpose and resilience.
D.J. Stewart has a few choice words for glioblastoma, which he’s faced with defiant optimism. Now he’s joining the larger rebellion against brain cancer.
Bruce and Kelly Stahlman found strength in gratitude as they raised, and then lost, twin boys with disabilities. They have faced Bruce’s glioblastoma with the same relentless spirit.
why innovation takes courage
Joachim believes that at the heart of every innovation is courage. He communicates the stories of his colleagues to encourage others.
supporting investigators in TTFields clinical trials
As many physicians are using TTFields therapy for the first time to treat their patients in clinical trials, Jonathan Gephart educates them on the science and administration of TTFields therapy.
empathy for candidates and colleagues
Whether he is helping a manager lead a team or interviewing a candidate for an open role, Jürgen Schaller seeks to understand the other person’s perspective.
working with patients is a privilege
When Caleigh Olds visits patients at their homes to provide technical support for TTFields therapy, she is motivated by their positive attitude and determination.
‘part of something meaningful’
At Novocure, we have the opportunity to dream big and inspire one another to be the best versions of ourselves. Every day, we strive to apply knowledge, advance skills and grow personally and professionally.
exploring the potential of TTFields therapy
It's an exhilarating time to highlight our research leadership and demonstrate that there is much more work to be done.
Our Global Supply Chain team is building the backbone for our anticipated growth.
investing in true innovation
From the moment Lennart Perlhagen met Novocure founder Professor Yoram Palti, Lennart felt inspired by Yoram’s brilliant mind. In 2000, Yoram shared with Lennart his idea of using electric fields to treat cancer. Lennart understood the risk was very high. He knew that it would be an immense challenge to develop an entirely new cancer treatment and to bring it to patients. However, that didn’t stop him.
Novocure joins New Hampshire Life Sciences
We will work with industry partners to champion New Hampshire’s cutting-edge life sciences sector and improve patients’ lives.
extra in the ordinary
Share stories of finding purpose and joy in simple moments while living with GBM.
you are not alone in facing a cancer diagnosis
Lean on patient advocacy groups for the support you need.
a Q&A with our founder
Novocure founder Professor Yoram Palti, recipient of the 2022 Israel Prize for excellence in entrepreneurship and technological innovation, reflects on his discovery of Tumor Treating Fields.
Novocure pledges $250K to Families First Health and Support Center
We committed the lead corporate gift to the capital campaign for a New Hampshire community health center’s new home.
lighting the world blue
Mesothelioma Awareness Day takes place annually in the U.S. on Sept. 26.
standing with the brain tumor community
As a global oncology company focusing on improving survival in some of the most aggressive forms of cancer, Novocure proudly stands with the brain tumor community during May for Brain Tumor Awareness Month (BTAM).
Ignace Vergote, Novocure Clinical Trial Investigator
Professor Ignace Vergote has dedicated his 32-year career to investigating treatment options and striving to improve survival in gynecologic cancers. Among gynecologic cancers, ovarian cancer is the deadliest, representing the fifth most common cause of cancer death among women in the United States. Five-year survival in ovarian cancer has slowly increased from 34 percent in 1975 to 47 percent today.